Recovery of Resistant Alopecia Areata Treated with Tofacitinib: An 8-Year-Old Child's Case Report

January 2022 in “ International Journal of Trichology ”

Anil B Bhokare

TLDR Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on journals.lww.com →

Discuss this study in the Community →

Cited in this study

8 / 8 results

research Treatment of Alopecia Areata in Pre-Adolescent Children with Oral Tofacitinib: A Retrospective Study

26 citations , October 2020 in “Pediatric Dermatology”

Oral tofacitinib may effectively treat hair loss in children with alopecia areata.

research Tofacitinib Therapy for Children with Severe Alopecia Areata

39 citations , April 2019 in “Journal of the American Academy of Dermatology”

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

research An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review

5 citations , August 2018 in “PubMed”

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations , July 2018 in “Journal of Investigative Dermatology”

Tofacitinib may help treat severe hair loss, but more research is needed.

research Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis

49 citations , June 2018 in “Journal of the American Academy of Dermatology”

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

research Treatment of Alopecia Areata With Tofacitinib

78 citations , June 2017 in “JAMA Dermatology”

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class

355 citations , April 2017 in “Journal of the American Academy of Dermatology”

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , January 2017 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

5 / 5 results

research Alopecia Areata: A Multifactorial Autoimmune Condition

148 citations , March 2019 in “Journal of autoimmunity”

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

research Case Report of Novel Combination of Anthralin and Calcipotriene Leading to Trichologic Response in Alopecia Areata

6 citations , March 2019 in “JAAD case reports”

A new mix of anthralin and calcipotriene might help treat severe hair loss.

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

4 citations , July 2018 in “PubMed”

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.

research Treating Resistant Cases of Alopecia Universalis

May 2018 in “Journal of cosmetology & trichology”

Combining platelet-rich plasma therapy with prostaglandin-F eye drops can significantly regrow hair in alopecia universalis.

research Overview of Alopecia Areata

110 citations , December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings”

Alopecia areata is a genetic and immune-related hair loss condition that is often associated with other autoimmune diseases and does not typically cause permanent damage to hair follicles.